Here’s what you should know:
1. Glenmark could use the compound as a monotherapy or in combination with approved treatments.
2. The companies didn’t disclose the deal’s terms.
3. The compound is currently in a phase II proof-of-concept study.
4. APC Therapeutics Co-Founders Vinod Patel and Venkateshwar Reddy said to GEN, “Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer.”
More articles on gastroenterology:
Exact Sciences pockets $245M in stock sale & more — 6 GI company key notes
The biggest problem in gastroenterology & how to fix it — Texas Digestive Disease Consultants CEO Dr. James Weber sheds insight
GI practice to know: Illinois Gastroenterology Group
